

Canada's Largest Heart Health Centre Orders VMS+ Complete Heart Analysis System

Toronto, Ontario, March 25, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the University of Ottawa Heart Institute has ordered the VMS+ complete heart analysis system for the clinical assessment of cardiac patients.

The new system will be used to do research into valvular heart disease, infective endocarditis and aortic diseases with a specific focus in the application of ultrasound in the study of cardiac structure and function.

Function of the right ventricular (RV) is increasingly recognized as an important predictor of outcome in various forms of heart disease. Although cardiac magnetic resonance (CMR) is accepted as the reference standard in the assessment of RV volume and function, its use is hindered by limited accessibility. Echocardiography (echo) is widely used in the assessment and follow-up of patients with suspected RV dysfunction, but it suffers from suboptimal endocardial visualization, inability to visualize the entire RV and only a qualitative rather than a quantitative assessment.

The initial research focus will be on patients with tricuspid regurgitation, testing the hypothesis that RV volume determined by the Ventripoint system can be used as a more reliable and quantitative method to assess and follow patients with tricuspid regurgitation.

The VMS+ system uses Artificial Intelligence (AI) to provide a streamlined approach for volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo images. It is also the only approved way to generate substantially equivalent results to the gold-standard MRI.

About University of Ottawa Heart Institute

The University of Ottawa Heart Institute (<https://www.ottawaheart.ca>) has flourished into one of Canada's most distinguished heart health centres for the unparalleled care it provides to its patients, a world-renowned research Institute that brings science from bench to bedside, and the country's main influencer when it comes to preventing heart disease. Its promise remains the very pillar on which it was built: Always putting patients first.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release